Video Experimental Relacionado
Updated: Jan 18, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
607
Terapia farmacológica para la angiodisplasia gastrointestinal
Rita Tinoco Magalhães1, Rita Valadas1, Patrícia Cipriano1
1Internal Medicine Department, Hospital de Cascais Dr. José de Almeida, Portugal.
Medicina clinica
|January 15, 2026
Resumen
Los tratamientos farmacológicos para la angiodisplasia gastrointestinal (AGD) son prometedores, y la octreotida demuestra eficacia y efectos secundarios mínimos. Se necesita más investigación para la talidomida y estudios comparativos para guiar la práctica clínica para el sangrado gastrointestinal oscuro.
Área de la Ciencia:
- Gastroenterología
- Farmacología
Sus antecedentes:
- La angiodisplasia gastrointestinal (AGD) es una causa frecuente de sangrado gastrointestinal oscuro.
- Las intervenciones farmacológicas son cruciales para los casos de AGD que no responden al tratamiento endoscópico o en localizaciones de difícil acceso quirúrgico.
Objetivo del estudio:
- Revisar y analizar las estrategias de manejo farmacológico para la AGD.
- Evaluar la eficacia y seguridad de la terapia hormonal, la talidomida y la octreotida en el tratamiento de la AGD.
Principales métodos:
- Se realizó una búsqueda exhaustiva de la literatura para identificar estudios relevantes.
- Los estudios incluidos se centraron en tratamientos farmacológicos para la AGD, específicamente terapia hormonal, talidomida y octreotida.
- Se analizaron datos de 59 publicaciones después de revisar 325 referencias.
Principales resultados:
- La terapia hormonal mostró una eficacia inconsistente y efectos secundarios notables.
- La talidomida presentó beneficios potenciales pero se asoció con eventos adversos significativos.
- La octreotida demostró eficacia con un perfil de seguridad favorable, particularmente su formulación de acción prolongada.
Conclusiones:
- La octreotida y la talidomida representan opciones terapéuticas prometedoras para la AGD.
- Se necesita más investigación, incluidos estudios comparativos, para evaluar completamente la eficacia y seguridad de estos agentes e informar la toma de decisiones clínicas.
Videos de Conceptos Relacionados
01:26Peptic Ulcer Disease IV: Management
439
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
439
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
01:17Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
900
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
900